What Bio.xyz does

Bio.xyz, operating as Bio Protocol, is a decentralized science (DeSci) financial layer built on Ethereum, Solana, and Base that enables community-driven funding, development, and governance of tokenized scientific research. The platform serves scientists, patients, crypto natives, and biotech founders through a suite of products including the BIOS AI Scientist (a general-purpose biomedical AI ranked #1 on bioinformatics benchmarks at 90% accuracy and used by 1,500+ researchers), autonomous BioAgents (Aubrai for longevity, PeptAI for peptide discovery, D1ckGPT for men's health, BiomeAI for microbiome), IP-Tokens for fractionalizing intellectual property, and a Launchpad for BioDAO token sales via Ignition Sales. The protocol is operated by the Bio.xyz Association, a not-for-profit entity in Zug, Switzerland, and issues the BIO token (total supply 3.32B) which trades on Binance, Uniswap, Jupiter, Robinhood, and Upbit.

The business model is crypto-native and multi-stream: revenue is generated through launchpad and Ignition Sale transaction fees, BioXP loyalty point minting at $0.01 per XP paid in BIO, BIOS API pay-per-query pricing settled in USDC via the x402 protocol, and BIO token trading activity. Distribution is self-serve through the web app at app.bio.xyz and ai.bio.xyz, supported by a global community via Discord, Telegram, X, the DeSci Pilled podcast, and sponsored DeSci events in Berlin, Singapore, Seoul, Boston, Lisbon, Turkiye, and Abu Dhabi. Headcount is 11–50, with named AI, product, ecosystem, and marketing leadership and strategic backers including Binance Labs, Arthur Hayes' Maelstrom Fund, Pfizer Ventures (via VitaDAO), 1kx, YZi Labs, and Northpond Ventures.

Since the July 2021 launch of VitaDAO as the first BioDAO, Bio Protocol has grown to support 10+ specialized BioDAOs across therapeutic areas (longevity, women's health, brain health, psychedelics, hair loss, cryopreservation, rare diseases, synthetic biology), aggregated over $200M in BioDAO token market cap by November 2023, raised $33M+ in the November 2024 BIO Genesis event, and closed a $6.9M round anchored by Maelstrom in September 2025. The BIO token generation event went live on January 3, 2025 on Binance, Ethereum Mainnet, and Solana.

Name

Bio.xyz

Legal name

Bio.xyz Association

Website

https://bio.xyz

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Bio.xyz operates the Bio Protocol, a decentralized science financial layer on Ethereum, Solana, and Base that enables community funding and governance of tokenized biotech research via the BIOS AI Scientist, autonomous BioAgents, IP-Tokens, and a Launchpad for BioDAOs serving scientists, patients, and crypto natives.

Ownership category

akta.pro rank

Product category

Decentralized Science (DeSci) Protocol

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (51321)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Decentralized science
• Biotech tokenization
• AI drug discovery
• Scientific IP tokens
• BioDAO governance

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Token Generation & Trading: BIO Protocol generates revenue through its native BIO token. The token provides access to whitelists in BioDAO funding rounds, governance rights, and rewards for contributing to BioDAOs. Trading occurs on Binance, Uniswap, Jupiter, and Robinhood.
2. Launchpad Fees: Bio Protocol operates a launchpad for BioDAOs and BioAgents. Ignition Sales and token launches generate fees. The platform takes a portion of fundraising rounds and token sales.
3. BioXP Program: BioXP can be minted by spending BIO at $0.01 per XP. This creates additional demand for BIO token while providing priority access benefits to BioXP holders.
4. BIOS API Usage: BIOS AI Scientist is available via API with pay-per-query pricing settled via x402. Agents and applications pay for deep research queries, literature searches, and data analysis.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Bio.xyz operates the Bio Protocol, a blockchain-based decentralized science (DeSci) financial layer that enables anyone to fund, develop, and govern tokenized scientific innovations. Its core offerings include BIOS, a general-purpose AI Scientist for biomedical research; BioAgents, autonomous AI agents that run discovery pipelines and commission wet-lab work; and a launchpad with Ignition Sales for community-driven biotech token distribution across a network of 10+ specialized BioDAOs covering longevity, neuroscience, psychedelics, synthetic biology, cryopreservation, and rare diseases.

Product overview

Bio.xyz is a decentralized science (DeSci) protocol serving as the operating and capital layer for autonomous scientific research. The platform consists of a unified ecosystem with the Bio Protocol as the core infrastructure, supported by the Bio Launchpad for token distribution, BIOS AI Scientist for research automation, and BioAgents as autonomous AI workers. Key products include Ignition Sales (token launches), BioXP (loyalty points), veBIO (governance staking), and 20+ specialized BioDAOs (VitaDAO, AthenaDAO, HairDAO, CerebrumDAO, PsyDAO, ValleyDAO, CryoDAO, Curetopia, SpineDAO, Quantum Biology DAO, Long COVID Labs, and more). Science Beach provides the social layer for deploying autonomous science agents in virtual biotech labs. The platform enables AI agents to finance and execute science end-to-end, with BIOS ranking #1 on bioinformatics benchmarks at 90% accuracy, used by 1,500+ researchers.

Differentiator

Problem solved

Functional benefit

Products and services

• Bio Protocol DeSci's financial layer enabling anyone to fund, develop and govern tokenized scientific innovations from universities, companies, and researchers worldwide.
• BIOS (Bio Intelligence System) General-purpose AI Scientist that handles complex biomedical research by orchestrating specialized scientific subagents, used by 1,500+ researchers and labs for drug and medicine development.
• BioAgents Autonomous AI agents ('agentic science machines') executing R&D tasks 24/7, including literature reading, hypothesis generation, experiment design, and wet-lab commissioning via x402 wallets.
• Bio Launchpad Launchpad platform for third-party token distribution by BioDAOs and BioAgents, including Ignition Sales, ecosystem airdrops, permissionless pools, and limit-sell fundraising.
• Ignition Sales Low-cap fundraise mechanism where BIO token holders commit tokens to curate BioDAOs and gain early access to new biotech token launches.
• BioXP Loyalty points system earned through BIO and ecosystem token staking, providing priority allocation in Ignition Sales; mintable instantly at $0.01 per XP.
• veBIO (Staking) Staking mechanism for BIO token holders providing automatic airdrops from new token launches, passive yield, and priority allocation in Ignition Sales.
• BioDAOs Community-owned R&D networks developing tokenized biotech assets in specific therapeutic areas such as longevity (VitaDAO), women's health (AthenaDAO), and cryopreservation (CryoDAO).
• Science Beach Social layer for autonomous science enabling creation of role-based virtual biotech labs where agents coordinate agent-to-agent, publish hypotheses, and commission wet lab experiments.
• Bio Markets Trading platform for BioDAO tokens and IP-Tokens with secondary-market trading via AMM liquidity pools paired with BIO.
• BIOS API Developer API for BIOS AI Scientist with pay-per-query pricing settled via x402 on Base, enabling third-party agents and apps to integrate biomedical research capabilities.
• PeptAI Autonomous AI agent fleet for peptide drug discovery; each agent targets a specific receptor and runs the full 9-gate discovery pipeline, publishing results openly on Science Beach.
• Aubrai Longevity AI co-scientist BioAgent co-developed with VitaDAO and Dr. Aubrey de Grey; first AI agent to commission wet-lab experiments and produce a scientific IP-Token.
• Shop.bio.xyz E-commerce storefront selling science-backed products developed by BioDAOs, such as HairDAO's FolliCool shampoo.

Quantifiable outcome

• 90% accuracy on BixBench Verified 50 bioinformatics benchmark
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability11 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Coinbase (x402)coreTechnology or Integration · 1 January 2025Coinbase's x402 payment protocol is integrated into Bio's Scientific AI Agents to enable autonomous agent-to-agent and agent-to-lab commerce with micropayments settling via USDC.
• MoleculecoreStrategic or Co-development Partner · 1 January 2025Molecule and Bio co-developed Science Beach, a social network for biological agents. Molecule's Labs platform provides wet lab execution and IP protection for BioAgent research outputs.
• Ginkgo BioworksmajorTechnology or Integration · 1 January 2025Ginkgo Bioworks provides wet lab experiment execution for Bio agents. When promising pathways emerge, agents can commission real wet lab experiments through Ginkgo's cloud lab services.
• Adaptyv BiomajorTechnology or Integration · 1 January 2025Adaptyv Bio provides synthesis services for peptide candidates generated by BIOS AI Scientist. Integrated via x402 for autonomous ordering and payment.
• OpenClawmajorTechnology or Integration · 1 January 2025OpenClaw agent framework is used to deploy BioAgents including Aubrai and BIOS-powered agents. The platform enables AI agents to access BIOS deep research API and interact with Beach Science.
• Newcastle UniversitymajorStrategic or Co-development Partner · 1 June 2023First IP-Token launched out of Newcastle University in June 2023, demonstrating the university's ability to tokenize and commercialize research via the Bio Protocol.
• University of CopenhagenmajorStrategic or Co-development Partner · 1 August 2021Bio's first science was funded on-chain in partnership with the University of Copenhagen in August 2021, establishing the model for academic partnerships.
• ResearchHubmajorStrategic or Co-development PartnerResearchHub and Bio Protocol have a symbiotic relationship. ResearchHub serves as a peer review and de-risking engine for BioDAOs, which use the platform for micro-experiments and to improve deal flow. ResearchHub Coin (RSC) was a Genesis network token.
• AerodromemajorTechnology or IntegrationAerodrome provides liquidity pool infrastructure for Bio Protocol-owned assets and BIO token trading. AUBRAI liquidity was migrated to Aerodrome and staked to earn emissions.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Molecule: Molecule is the closest direct peer: a DeSci platform for IP-NFTs and on-chain research funding that co-developed Science Beach with Bio.xyz and operates the Molecule Labs wet-lab execution layer used by Bio's agents. Both target scientists, patients, and crypto natives funding early-stage science via tokenized IP.
• ResearchHub: ResearchHub is a DeSci peer-review and micro-experiment platform that was a Genesis network token alongside BIO and serves as a 'peer review and de-risking engine' for BioDAOs. Comparable as decentralized science infrastructure serving scientists and patient communities.
• VitaDAO: VitaDAO is both the founding BioDAO inside Bio.xyz and a standalone longevity research DAO. It operates a similar model of tokenized governance over early-stage longevity science and is a partial unit-of-analysis within the Bio.xyz ecosystem but functions independently as a comparable DeSci DAO.

Broad incumbents

• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery incumbent with a Pharma.AI platform that overlaps with BIOS in target identification, generative chemistry, and clinical-trial prediction. It represents the established pharma-AI competitor that BIOS benchmarks against.
• Recursion Pharmaceuticals: Recursion is a publicly-listed AI-driven biotech combining high-throughput wet-lab experimentation with proprietary ML models for target and drug discovery — a direct competitor to the BIOS wet-lab + AI pipeline Bio.xyz orchestrates via Ginkgo, Adaptyv, and Molecule.
• Isomorphic Labs: Isomorphic Labs (Alphabet-owned) is a leading AI-first drug design company applying deep learning to biology. Comparable to Bio.xyz's BIOS in its goal of automating drug discovery, but with deeper capital, proprietary data, and pharma partnerships (e.g., Novartis, Eli Lilly).
• Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science that overlaps with BIOS's in-silico screening and molecular dynamics scoring capabilities for protein/peptide design.
• Benchling: Benchling is a cloud-based R&D platform used by 1,200+ biotech companies for experiment tracking, molecular biology, and registry management — adjacent infrastructure to BIOS for capturing wet-lab data and feeding structured outputs back into the discovery pipeline.

Emerging players

• Genesis Therapeutics: Genesis Therapeutics is an AI-native drug discovery company combining molecular simulation, generative models, and foundation models for protein/ligand design — a younger, more specialized competitor to BIOS's PeptAI-style peptide drug-discovery workflow.

Others

• Coinbase: Coinbase is the developer of the x402 payment protocol that Bio.xyz integrated for agent-to-agent and agent-to-lab micropayments. It is an enabling infrastructure partner — not a competitor — but critical to the autonomous-science commerce thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bioprotocol
• LinkedInlinkedin.com/company/bioprotocol

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio.xyz